| Literature DB >> 34216543 |
Jaclyn M Einstein1, Mark Perelis1, Isaac A Chaim1, Jitendra K Meena2, Julia K Nussbacher1, Alexandra T Tankka1, Brian A Yee1, Heyuan Li2, Assael A Madrigal1, Nicholas J Neill2, Archana Shankar1, Siddhartha Tyagi2, Thomas F Westbrook3, Gene W Yeo4.
Abstract
RNA-binding proteins (RBPs) are critical regulators of post-transcriptional gene expression, and aberrant RBP-RNA interactions can promote cancer progression. Here, we interrogate the function of RBPs in cancer using pooled CRISPR-Cas9 screening and identify 57 RBP candidates with distinct roles in supporting MYC-driven oncogenic pathways. We find that disrupting YTHDF2-dependent mRNA degradation triggers apoptosis in triple-negative breast cancer (TNBC) cells and tumors. eCLIP and m6A sequencing reveal that YTHDF2 interacts with mRNAs encoding proteins in the MAPK pathway that, when stabilized, induce epithelial-to-mesenchymal transition and increase global translation rates. scRibo-STAMP profiling of translating mRNAs reveals unique alterations in the translatome of single cells within YTHDF2-depleted solid tumors, which selectively contribute to endoplasmic reticulum stress-induced apoptosis in TNBC cells. Thus, our work highlights the therapeutic potential of RBPs by uncovering a critical role for YTHDF2 in counteracting the global increase of mRNA synthesis in MYC-driven breast cancers.Entities:
Keywords: CRISPR screening; MYC-driven cancer; N6-methyladenosine; RNA-binding protein; STAMP; YTHDF2; scRNA-seq
Mesh:
Substances:
Year: 2021 PMID: 34216543 PMCID: PMC8359670 DOI: 10.1016/j.molcel.2021.06.014
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 19.328